Corvus Pharmaceuticals, Inc. (CRVS) stock forecast and price target
Price $10.64 · data as of November 13, 2026
12-month price target
Average target$31.50
Upside / downside+196.1%
Analysts6
ConsensusStrong buy
Low $27.00Average $31.50High $42.00
Gold marker: average target · white marker: today’s price ($10.64)
Analyst ratings
Strong buy 1Buy 5Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.80 | −49.4% | $0 |
| Next fiscal year ends December 31, 2027 | $-1.10 | −37.1% | $2M |
| Next quarter ends December 31, 2026 | $-0.23 | −56.7% | $0 |
| Quarter after ends March 31, 2027 | $-0.27 | −80.0% | $0 |
Consensus of the analysts covering Corvus Pharmaceuticals, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the Corvus Pharmaceuticals stock price target?
The average 12-month target from 6 analysts is $31.50, 196.1% above the current price of $10.64 Targets range from $27.00 to $42.00.
Is Corvus Pharmaceuticals a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 5 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Corvus Pharmaceuticals expected to earn?
Analysts expect EPS of $-0.80 for the fiscal year ending December 31, 2026 and $-1.10 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.